Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 118 recommendations for 72 medicines and 27 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
Biological
  1. BCG vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tuberculosis
  2. Japanese encephalitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  3. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Juvenile idiopathic arthritis
  4. Ansuvimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 400 mg powder for injection
    Indications
    Ebola virus disease
  5. Anti-D immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
    Indications
    Rh incompatibility reaction Maternal care for red cell antibodies
  6. Anti-rabies immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
    Rabies
  7. Anti-rabies virus monoclonal antibodies General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
    Rabies
  8. Anti-tetanus immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
    Tetanus
  9. Antivenom immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  10. Asparaginase General information
    Section
    Cytotoxic medicines
    • Powder for injection: 10 000 IU in vial.
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified
  11. Atezolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Hepatocellular carcinoma of liver
  12. Atoltivimab + maftivimab + odesivimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
    Indications
    Ebola virus disease
  13. Axicabtagene ciloleucel General information
    Section
    Antineoplastics and supportive medicines
    • Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.
    Indications
    Diffuse large B-cell lymphomas
  14. Beractant General information
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 25 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  15. Bevacizumab General information
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
    Indications
    Age related macular degeneration
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion
    Indications
    Hepatocellular carcinoma of liver
  16. Cemiplimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach
  17. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  18. Cholera vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against cholera alone
  19. Coagulation factor IX complex General information
    Section
    Coagulation factors
    Indications
    Therapeutic equivalent to coagulation factor IX, plasma-derived for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX, plasma-derived for Haemophilia B
  20. Coagulation factor IX, plasma-derived General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B
  21. Coagulation factor VIII, plasma-derived General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Haemophilia A
  23. Cryoprecipitate (pathogen-reduced) General information
    Section
    Blood and blood components
    • Injection: frozen liquid in bag or lyophilized powder in vial containing:
    • > 50 IU Factor VIII
    • > 100 IU vWF
    • > 140 mg clottable fibrinogen per unit
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage Haemophilia A Von Willebrand disease
  24. Dalteparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  25. Darbepoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia
  26. Dengue vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  27. Diphtheria antitoxin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
    Indications
    Need for immunization against diphtheria alone
  28. Diphtheria vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria alone
  29. Dostarlimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of corpus uteri
  30. Dulaglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  31. Durvalumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion
    Indications
    Hepatocellular carcinoma of liver Malignant neoplasms of biliary tract, distal bile duct Malignant neoplasm of intrahepatic bile ducts Malignant neoplasms of gallbladder Malignant neoplasms of proximal biliary tract, cystic duct
  32. Emicizumab General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial
    Indications
    Haemophilia A
  33. Enoxaparin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  34. Epoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia
  35. Epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
    Section
    Supportive medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia
  36. Epoetin theta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  37. Eptinezumab General information
    Section
    Medicines for migraine prophylaxis
    Indications
    Therapeutic equivalent to fremanezumab for Chronic migraine
  38. Equine rabies immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
    Rabies
  39. Erenumab General information
    Section
    Medicines for migraine prophylaxis
    Indications
    Therapeutic equivalent to fremanezumab for Chronic migraine
  40. Erythropoiesis-stimulating agents General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
    Section
    Supportive medicines
    • Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)
    Indications
    Drug-induced aplastic anaemia
  41. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  42. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  43. Fremanezumab General information
    Section
    Medicines for migraine prophylaxis
    • Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe
    Indications
    Chronic migraine
  44. Fresh-frozen plasma General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  45. Galcanezumab General information
    Section
    Medicines for migraine prophylaxis
    Indications
    Therapeutic equivalent to fremanezumab for Chronic migraine
  46. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  47. Haemophilus influenzae type b vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  48. Hepatitis A vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  49. Hepatitis B vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  50. Human papilloma virus (HPV) vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  51. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  52. Influenza vaccine (seasonal) General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against influenza
  53. Insulin (analogue, long-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  54. Insulin (human, intermediate-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  55. Insulin (human, short-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  56. Insulin degludec General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  57. Insulin detemir General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  58. Insulin glargine General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  59. Ipilimumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Melanoma of skin
  60. Liraglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  61. Lisocabtagene maraleucel General information
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas
  62. Measles vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against measles alone
  63. Meningococcal meningitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  64. Methoxy polyethylene glycol-epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  65. Mumps vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against mumps alone
  66. Nadroparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  67. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
    • Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Adenocarcinoma of oesophagogastric junction Adenocarcinoma of stomach
  68. Normal immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
    Indications
    Primary immunodeficiencies Langerhans cell histiocytosis Mucocutaneous lymph node syndrome
    Section
    Medicines for Guillain-Barré syndrome
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    Indications
    Acute inflammatory demyelinating polyneuropathy
  69. Ocrelizumab General information
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution
    Indications
    Multiple sclerosis
  70. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  71. Pegfilgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  72. Pegylated interferon alfa (2a) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  73. Pegylated interferon alfa (2b) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  74. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of large intestine Other specified malignant neoplasms of bronchus or lung Adenocarcinoma of stomach Squamous cell carcinoma of hypopharynx and variants Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Carcinoma of breast, specialised type Squamous cell carcinoma of nasopharynx Squamous cell carcinoma of oesophagus Malignant neoplasms of oesophagogastric junction Therapeutic equivalent to nivolumab for Melanoma of skin
  75. Pertussis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against pertussis alone
  76. Platelets General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  77. Pneumococcal vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  78. Poliomyelitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against poliomyelitis
  79. Rabies vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rabies
  80. Red blood cells General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  81. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphoma, not otherwise specified
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
    Indications
    Multiple sclerosis
  82. Rotavirus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  83. Rubella vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rubella alone
  84. Semaglutide General information
    Section
    Hypoglycaemic agents
    • Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL
    Indications
    Type 2 diabetes mellitus
  85. Tetanus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tetanus alone
  86. Tick-borne encephalitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against arthropod-borne viral encephalitis
  87. Tirzepatide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  88. Tisagenlecleucel General information
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas
  89. Tislelizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung
  90. Toripalimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 240 mg per 6 mL in vial
    Indications
    Malignant neoplasms of nasopharynx Squamous cell carcinoma of oesophagus
  91. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  92. Tremelimumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion
    Indications
    Hepatocellular carcinoma of liver Other specified malignant neoplasms of bronchus or lung
  93. Typhoid vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against typhoid-paratyphoid alone
  94. Ustekinumab General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen
    Indications
    Psoriasis of unspecified type
  95. Varicella vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  96. Whole blood General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  97. Yellow fever vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases